<DOC>
	<DOCNO>NCT01514929</DOCNO>
	<brief_summary>The purpose study determine study drug , ACHN-490 Injection , affect QT interval normal volunteer . The hypothesis drug cause increase QT interval .</brief_summary>
	<brief_title>A Study Evaluate Effect IV ACHN-490 Injection QT/QTc Interval Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Male female subject 18 50 year age body mass index ≥ 18 ≤ 33 kg/m2 , weight ≥ 40 ≤ 100 kg inclusive . 2 . Subject good health judge investigator base laboratory criterion clinically significant finding medical history physical examination . 3 . Females childbearing potential ( define less one year postmenopause ) eligible enrollment breast feeding , negative serum pregnancy test study entry , use highly effective method contraception least 3 month study drug administration , study , least 6 month study completion . 4 . Subjects willing comply study activity procedures provide write informed consent prior study procedure sign date Health Insurance Portability Accountability Act ( HIPAA ) authorization form . 1 . A history additional risk factor TdP . 2 . Unstable cardiovascular disease , include recent myocardial infarction cardiac arrhythmia . 3 . Sustained supine systolic blood pressure &gt; 150 mmHg , &lt; 110 mmHg Part 1 &lt; 100mmHg Part 2 , diastolic blood pressure &gt; 95 mmHg screen baseline . 4 . A rest pulse rate rest , take screening , &lt; 40 bpm &gt; 100 bpm . 5 . An abnormal screening ECG indicate second thirddegree atrioventricular ( AV ) block , one following : QRS &gt; 110 millisecond ( msec ) , QTcB &gt; 470 msec female 450 msec male , PR interval &gt; 240 msec , rhythm sinus rhythm , interpret Investigator clinically significant . 6 . Uncontrolled hypertension , asthma , unstable diabetes ( type I type II ) , thyroid disease , seizures , myasthenia gravis , neuromuscular disorder . 7 . Positive result screen hepatitis B virus , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) infection . 8 . History central nervous system disorder , epilepsy know seizure disorder ( exclude history childhood febrile seizure ) . 9 . The subject history cancer , except basal cell stage 1 squamous cell carcinoma skin , remission least 5 year prior first dose study drug . 10 . Subjects condition possibly affect drug absorption . 11 . History significant hearing loss family history hearing loss , exclude age relate ( ≥ age 65 ) hearing loss . A prior diagnosis sensorineural hearing loss Ménière 's disease . 12 . Clinically significant illness , include viral syndrome within 3 week dose . 13 . The use concomitant medication prolong QT/QTc interval . 14 . Used prescription medication , overthecounter ( OTC ) medication , investigational medications/therapy , vitamin , nicotinecontaining product ( eg , cigarette , cigar , chew tobacco , snuff , etc . ) within 28 day 5 halflives , whichever longer , dose ACHN490 Injection . 15 . Used aminoglycosides within 6 month prior IMP administration . 16 . Used herbal preparation include St. John 's wort , ginseng , kava kava , ginkgo biloba , melatonin , nutraceuticals within 28 day prior IMP administration . 17 . Consumed caffeine xanthinecontaining product ( eg , tea , coffee , chocolate , cola , etc . ) , Seville oranges ( sour ) , grapefruit , grapefruit juice , fish liver oil within 72 hour prior IMP administration . 18 . Current participation clinical study investigational product . 19 . Consumed 28 unit ethanol per week time 6 month dose ( 1 unit ethanol equivalent 8 ounce beer , 4 ounce wine , 1 ounce spirit ) history alcoholism and/or drug/chemical abuse . Also , consumption amount ethanol within 72 hour ACHN490 Injection dose . 20 . Donated blood blood component within 60 day prior receive study drug . 21 . Women pregnant ( plan become pregnant within next 3 month ) currently breastfeed . 22 . Previous participation ACHN490 Injection study . 23 . Known hypersensitivity aminoglycosides component ACHN490 Injection . 24 . Subjects poor venous access . 25 . Unable understand verbal write English language certify translation inform consent available . 26 . Any medical , psychological , social condition , opinion PI medical monitor , would prevent subject fully participate study would represent concern study compliance would constitute safety concern subject . 27 . An employee investigator study center direct involvement propose study study direction Investigator study center , well family member employee investigator . 28 . * ( Part 1 ) * Acceptable reproducible spirometry measurement define : forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) &lt; 80 % predict FEV1/FVC ratio &lt; 70 % predict . See Appendix 7 definition acceptability reproducibility . 29 . * ( Part 2 ) * Known hypersensitivity moxifloxacin quinolones . 30 . * ( Part 2 ) * Taken antacid , sucralfate , multivitamin , product multivalent cation within 8 hour oral dose Part 2 need take within 4 hour dose administration . 31 . * ( Part 2 ) * Taken warfarin Class IA Class III antiarrhythmic within one week prior study drug administration expect need take study period . 32 . * ( Part 2 ) * Participation Part 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Thorough QT</keyword>
</DOC>